TY - JOUR
T1 - Ambient ozone exposure is associated with eosinophil activation in healthy children
AU - Frischer, Thomas
AU - Gartner, Christian
AU - Halmerbauer, Gerhard
AU - Tauber, Erich
AU - Horak jr., Friedrich
AU - Koller, Dieter
N1 - Copyright:
Copyright 2008 Elsevier B.V., All rights reserved.
PY - 2001
Y1 - 2001
N2 - Background: Eosinophil activation is characteristic for allergic airways disease. However, eosinophilic airways inflammation has also been observed subsequent to ambient ozone exposure. Methods: For a population sample of 877 children living at nine sites with different ozone exposure we measured urinary eosinophil protein X (U-EPX) as a marker of eosinophil activation. U-EPX was determined from a single spot urine sample during autumn 1997. Children were participants in a longitudinal study of ozone effects on lung function. Results: The 5-95% percentiles of ozone exposure (30-day mean before test) were 11.8-51.5 p.p.b. (mean: 31.6 ppb). U-EPX was measured by radioimmunoassay and expressed as ratio to urinary creatinine (μg EPX/mmol creatinine). Log transformation was performed to achieve a normal distribution. LogU-EPX was associated with gender, a diagnosis of asthma and atopy (skin test sensitivity to any of seven aeroallergens). LogU-EPX increased with ozone exposure for all children. The medians of LogU-EPX according to the first-fourth quartiles of ozone exposure were: 1.82, 1.88, 1.95 and 2.03. For 172 non-asthmatic children who had spent the whole summer at their site corresponding figures were 1.57, 1.78, 2.07 and 2.13. In a multivariate model with logU-EPX being the dependent variable and adjusted for gender, site and atopy, ozone was found to be significant (estimate: 0.007 μg/mmol creatinine per ppb ozone; SE:0.02; P < 0.001). Conclusion: Our observation supports the hypothesis that ozone in healthy children is associated with eosinophil inflammation, most likely in the airways.
AB - Background: Eosinophil activation is characteristic for allergic airways disease. However, eosinophilic airways inflammation has also been observed subsequent to ambient ozone exposure. Methods: For a population sample of 877 children living at nine sites with different ozone exposure we measured urinary eosinophil protein X (U-EPX) as a marker of eosinophil activation. U-EPX was determined from a single spot urine sample during autumn 1997. Children were participants in a longitudinal study of ozone effects on lung function. Results: The 5-95% percentiles of ozone exposure (30-day mean before test) were 11.8-51.5 p.p.b. (mean: 31.6 ppb). U-EPX was measured by radioimmunoassay and expressed as ratio to urinary creatinine (μg EPX/mmol creatinine). Log transformation was performed to achieve a normal distribution. LogU-EPX was associated with gender, a diagnosis of asthma and atopy (skin test sensitivity to any of seven aeroallergens). LogU-EPX increased with ozone exposure for all children. The medians of LogU-EPX according to the first-fourth quartiles of ozone exposure were: 1.82, 1.88, 1.95 and 2.03. For 172 non-asthmatic children who had spent the whole summer at their site corresponding figures were 1.57, 1.78, 2.07 and 2.13. In a multivariate model with logU-EPX being the dependent variable and adjusted for gender, site and atopy, ozone was found to be significant (estimate: 0.007 μg/mmol creatinine per ppb ozone; SE:0.02; P < 0.001). Conclusion: Our observation supports the hypothesis that ozone in healthy children is associated with eosinophil inflammation, most likely in the airways.
KW - Children
KW - Epidemiology
KW - Inflammation
KW - Ozone
KW - Multivariate Analysis
KW - Cross-Sectional Studies
KW - Humans
KW - Male
KW - Eosinophil-Derived Neurotoxin
KW - Air Pollutants/adverse effects
KW - Female
KW - Eosinophils/immunology
KW - Ozone/adverse effects
KW - Child
KW - Ribonucleases/urine
UR - http://www.scopus.com/inward/record.url?scp=0035726376&partnerID=8YFLogxK
U2 - 10.1046/j.1365-2222.2001.01155.x
DO - 10.1046/j.1365-2222.2001.01155.x
M3 - Article
C2 - 11529890
SN - 0954-7894
VL - 31
SP - 1213
EP - 1219
JO - Clinical and Experimental Allergy
JF - Clinical and Experimental Allergy
IS - 8
ER -